Home › NDC Lookup › RxCUI directory › RxCUI 686429

Mesalamine 1200 MG Delayed Release Oral Tablet — RxCUI 686429

RxNorm drug concept · Semantic clinical drug
RxCUI 686429 Semantic clinical drug · SCD ● Current RxNorm concept 16 FDA products 23 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI686429
Official nameMesalamine 1200 MG Delayed Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asmesalazine 1.2 GM Delayed Release Oral Tablet; mesalamine 1.2 GM Delayed Release Oral Tablet, Once-Daily
FDA products mapped16
Package NDCs mapped23
Reported Medicaid activity (SDUD)80,447 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mesalamine Rectal: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Mesalamine rectal works by calming the inflammation directly in the lining of your rectum and lower colon — the area affected by your condition. It blocks some of the chemical sign...
  • What exactly is this medication doing for my colitis?
  • Treatment is typically continued for 3 to 6 weeks depending on your symptoms and what your doctor sees during examination. It's important to keep using it for the full course your...
  • How long do I need to use it before it starts working?
📖 Read our full Mesalamine Rectal guide →

🕸️ Concept Web — How Mesalamine 1200 MG Delayed Release Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Mesalamine 1200 MG Delayed Release Oral Tablet RxCUI 686429

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Mesalamine 52582
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Lialda 686430
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mesalamine Delayed Release Oral Tablet 372784
    • Mesalamine Oral Product 1165714
    • Mesalamine Pill 1165715
    • Mesalamine Delayed Release Oral Tablet [Lialda] 686432
    • Lialda Oral Product 1186167
    • Lialda Pill 1186168
    • Delayed Release Oral Tablet 10312
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Mesalamine 1200 MG SCDC · 686428
  • Mesalamine Delayed Release Oral Tablet SCDF · 372784
  • Mesalamine Oral Product SCDG · 1165714
  • Mesalamine Pill SCDG · 1165715

Brand-Name Concepts

📦 FDA Products & Package NDCs

16 products · 23 package NDCs
23 package NDCs map to RxCUI 686429 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00527-3012-48 120 TABLET, DELAYED RELEASE in 1 BOTTLE (0527-3012-48) MESALAMINE Lannett Company Inc. 2023-06-03
00591-2245-22 120 TABLET, DELAYED RELEASE in 1 BOTTLE (0591-2245-22) Mesalamine Actavis Pharma, Inc. 2018-03-26
00904-6832-04 30 BLISTER PACK in 1 CARTON (0904-6832-04) / 1 TABLET, DELA... mesalamine Major Pharmaceuticals 2017-06-19
31722-0043-05 500 TABLET, DELAYED RELEASE in 1 BOTTLE (31722-043-05) Mesalamine Camber Pharmaceuticals, Inc. 2024-02-05
31722-0043-12 120 TABLET, DELAYED RELEASE in 1 BOTTLE (31722-043-12) Mesalamine Camber Pharmaceuticals, Inc. 2024-02-05
51407-0900-12 120 TABLET, DELAYED RELEASE in 1 BOTTLE (51407-900-12) mesalamine Golden State Medical Supply, Inc. 2024-04-25
54092-0100-01 120 TABLET, DELAYED RELEASE in 1 BOTTLE (54092-100-01) Mesalamine Takeda Pharmaceuticals America, Inc. 2017-08-29
54092-0476-01 120 TABLET, DELAYED RELEASE in 1 BOTTLE (54092-476-01) Lialda Takeda Pharmaceuticals America, Inc. 2007-01-16
54092-0476-02 12 BOTTLE in 1 CARTON (54092-476-02) / 120 TABLET, DELAYED... Lialda Takeda Pharmaceuticals America, Inc. 2007-01-16
54092-0476-08 3 CARTON in 1 CARTON (54092-476-08) / 8 BLISTER PACK in 1 C... Lialda Takeda Pharmaceuticals America, Inc. 2007-01-16
54092-0476-12 120 TABLET, DELAYED RELEASE in 1 BOTTLE (54092-476-12) Lialda Takeda Pharmaceuticals America, Inc. 2007-01-16
60687-0397-25 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-397-25) / 1 TABL... Mesalamine American Health Packaging 2018-10-11
62135-0714-12 120 TABLET, DELAYED RELEASE in 1 BOTTLE (62135-714-12) Mesalamine Chartwell RX, LLC 2023-07-21
62135-0714-60 60 TABLET, DELAYED RELEASE in 1 BOTTLE (62135-714-60) Mesalamine Chartwell RX, LLC 2023-07-21
63304-0175-13 120 TABLET, DELAYED RELEASE in 1 BOTTLE (63304-175-13) Mesalamine Sun Pharmaceutical Industries, Inc. 2019-02-01
68382-0711-19 120 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-711-19) mesalamine Zydus Pharmaceuticals USA Inc. 2017-06-19
68382-0711-64 34 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-711-64) mesalamine Zydus Pharmaceuticals USA Inc. 2017-06-19
70771-1071-01 120 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1071-1) mesalamine Zydus Lifesciences Limited 2017-06-19
70771-1071-02 34 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1071-2) mesalamine Zydus Lifesciences Limited 2017-06-19
72162-2213-02 120 TABLET, DELAYED RELEASE in 1 BOTTLE (72162-2213-2) MESALAMINE Bryant Ranch Prepack 2024-05-29
72162-2231-02 120 TABLET, DELAYED RELEASE in 1 BOTTLE (72162-2231-2) Mesalamine Bryant Ranch Prepack 2024-08-14
72603-0304-01 120 TABLET, DELAYED RELEASE in 1 BOTTLE (72603-304-01) Mesalamine NorthStar RxLLC 2024-12-01
84612-0175-13 120 TABLET, DELAYED RELEASE in 1 BOTTLE (84612-175-13) Mesalamine Nuvaila Limited 2026-07-01
Observed labelers: Takeda Pharmaceuticals America, Inc. (5) · Bryant Ranch Prepack (2) · Camber Pharmaceuticals, Inc. (2) · Chartwell RX, LLC (2) · Zydus Lifesciences Limited (2) · Zydus Pharmaceuticals USA Inc. (2) · +8 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.8138
Range $0.8138–$8.9467 · middle 50% $0.8138–$0.8138 · 14 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.